Previous 10 | Next 10 |
- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma - Completed enrollment ...
2023-11-04 09:00:00 ET Summary iTeos Therapeutics is a clinical-stage biotech focused on developing immunotherapies for solid tumors, with a focus on non-small cell lung cancer (NSCLC). Their most advanced project is belrestotug, an antibody targeting the TIGIT immune checkpoint, ...
2023-10-11 18:04:12 ET S&P Dow Jones Indices said Wednesday that NCR Atleos ( NATL ) will replace iTeos Therapeutics ( ITOS ) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. iTeos Therapeutics is no longer representative of t...
NCR Atleos Set to Join S&P SmallCap 600 NCR Atleos Set to Join S&P SmallCap 600 PR Newswire NEW YORK , Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective ...
WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company m...
2023-08-23 13:11:49 ET Gainers: VCI Global Limited ( VCIG ) +107% . Mercurity Fintech Holding ( MFH ) +44% . Apellis Pharmaceuticals ( APLS ) +32% . iTeos Therapeutics ( ITOS ) +27% . Hitek Global ( HKIT ) +26% . Aditxt ( A...
2023-08-23 10:12:08 ET More on Healthcare sector XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air BofA experiences its thi...
2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...
2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...
2023-08-08 08:02:19 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q2 GAAP EPS of -$0.96. The company’s cash, cash equivalents, and investments position was $677.5 million as of June 30, 2023, as compared to $791.9 million as of June 30, 2022. For furth...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
2024-05-13 07:00:04 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $46.00 for ITOS on 2024-05-13 06:11:00. The adjusted price target was set to $46.00. At the time of the announcement, ITOS was trading at $17.44. ITOS currently trades -32.51% ver...
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...